{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:56:07Z","timestamp":1788436567125,"version":"build-2803163510"},"reference-count":83,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      This study advanced the preclinical development of a new dry powder aerosol synthetic lung surfactant (SLS) product for neonatal respiratory distress syndrome (RDS) by integrating a multiple-actuation device and scalable spray-dried formulation, evaluating physicochemical and\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      aerosol performance, and then comparing biological efficacy with the current clinical standard of high-volume liquid bolus instillation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A new high-dose air-jet dry powder inhaler was developed that was characterized by a variable-volume aerosolization chamber (D3 device) with the goal of unifying aerosol quality and emitted dose (ED) over multiple actuations. The SLS excipient enhanced growth dry powder formulation was advanced through production on a scalable nozzle-based spray dryer system (Mini Spray Dryer; MSD2 formulation). Physicochemical characterization of the formulation was performed along with\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      aerosol testing of the new D3-MSD2 device and formulation combination. The optimized D3-MSD2 aerosol therapy was then evaluated in a rabbit model of severe RDS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The new D3-MSD2 combination produced a small-particle aerosol with high fine particle fraction (FPF\n                      <jats:sub>&lt;5 \u00b5m<\/jats:sub>\n                      = 87.9%; FPF\n                      <jats:sub>&lt;2.5 \u00b5m<\/jats:sub>\n                      = 61.6%) and percent ED (77.4% of loaded). Additional\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      testing highlighted consistent particle size (D\n                      <jats:sub>v50<\/jats:sub>\n                      = 1.6 \u00b5m) and ED across multiple actuations. In the animal model experiments, a total device-loaded formulation mass of 60 mg (delivered as 2x30 mg) produced a total phospholipid (PL) dose of 24 mg-PL\/kg and a device ED of 18 mg-PL\/kg compared with the 200 mg-PL\/kg clinical dose of Curosurf liquid.\n                      <jats:italic toggle=\"yes\">In vivo<\/jats:italic>\n                      response rate for the D3-MSD2 aerosol therapy was considerably more rapid with arterial oxygenation recovering 5\u201312 times faster than for liquid Curosurf. Biological response for the D3-MSD2 aerosol therapy was also superior with 2-fold improvement in final lung compliance compared with liquid Curosurf.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The new D3-MSD2 aerosol therapy was found to be superior to clinical-practice liquid bolus instillation in the critical areas of required dose (order-of-magnitude reduction), delivery time, biological response rate, and efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jamp.2025.0001","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T12:10:19Z","timestamp":1745496619000},"page":"168-191","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Preclinical Testing of a New Dry Powder Aerosol Synthetic Lung Surfactant Formulation and Device Combination for the Treatment of Neonatal Respiratory Distress Syndrome"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-5691","authenticated-orcid":false,"given":"Worth","family":"Longest","sequence":"first","affiliation":[{"name":"Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia, USA."},{"name":"Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-1183","authenticated-orcid":false,"given":"Michael","family":"Hindle","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Farkas","sequence":"additional","affiliation":[{"name":"Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.M.","family":"Momin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Dalton","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghali","family":"Aladwani","sequence":"additional","affiliation":[{"name":"Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hattie","family":"KenKnight","sequence":"additional","affiliation":[{"name":"Center for Respiratory Biology and Therapeutics, Seattle Children\u2019s Research Institute, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"DiBlasi","sequence":"additional","affiliation":[{"name":"Center for Respiratory Biology and Therapeutics, Seattle Children\u2019s Research Institute, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.923010"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01585-9"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.03579"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.01306"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000499361"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3985"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1998.tb01469.x"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050588"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02189"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000346521"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-024-03754-7"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2020.1593"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2013.24"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119359"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.1.9812017"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199308000-00009"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1096-9"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101580"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02007-8"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1891\/0730-0832.28.4.221"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000244343"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/15513819409037691"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.23.289727"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2019.1589372"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.4155\/tde.13.72"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2019.05.005"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2020.101986"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-3967"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2018-315051"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.12899.2"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.403"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000369955"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198309000-00012"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1986.61.5.1741"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1990.69.6.2303"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1991.70.2.869"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-020-01324-2"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24603"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000508349"},{"key":"e_1_3_8_41_2","first-page":"9","article-title":"Aerosolized surfactants for the treatment of neonatal respiratory distress syndrome: Challenges and opportunities","volume":"1","author":"DiBlasi RM","year":"2024","unstructured":"DiBlasi RM, , KenKnight H. Aerosolized surfactants for the treatment of neonatal respiratory distress syndrome: Challenges and opportunities. Respiratory Drug Delivery, 2024; 1:9\u201320.","journal-title":"Respiratory Drug Delivery"},{"key":"e_1_3_8_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1220-x"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-010-1292-6"},{"key":"e_1_3_8_44_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2013.790362"},{"key":"e_1_3_8_45_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.04490653"},{"key":"e_1_3_8_46_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2013.1077"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24326"},{"key":"e_1_3_8_48_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-7265"},{"key":"e_1_3_8_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-024-03740-z"},{"key":"e_1_3_8_50_2","first-page":"21","article-title":"The dry powder route to highly effective aerosol surfactant therapy\u2014A little can go a long way","volume":"1","author":"Longest PW","year":"2024","unstructured":"Longest PW, , DiBlasi RM, , Momin MAM, et al. The dry powder route to highly effective aerosol surfactant therapy\u2014A little can go a long way. Respiratory Drug Delivery, 2024; 1:21\u201331.","journal-title":"Respiratory Drug Delivery"},{"key":"e_1_3_8_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1466-4"},{"key":"e_1_3_8_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2012.01476.x"},{"key":"e_1_3_8_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123199"},{"key":"e_1_3_8_54_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2020.1604"},{"key":"e_1_3_8_55_2","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.12799.2"},{"key":"e_1_3_8_56_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2017.1424"},{"key":"e_1_3_8_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2644-1"},{"key":"e_1_3_8_58_2","first-page":"527","article-title":"Spray characterization of low volume air-jet dry powder inhaler devices for the delivery of a synthetic lung surfactant (SLS) powder formulation","volume":"1","author":"Dalton CJ","year":"2024","unstructured":"Dalton CJ, , Momin MAM, , Farkas D, et al. Spray characterization of low volume air-jet dry powder inhaler devices for the delivery of a synthetic lung surfactant (SLS) powder formulation. Respiratory Drug Deliv, 2024; 1:527\u2013530.","journal-title":"Respiratory Drug Deliv"},{"key":"e_1_3_8_59_2","doi-asserted-by":"publisher","DOI":"10.3109\/10837450.2010.485320"},{"key":"e_1_3_8_60_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-01998-9"},{"key":"e_1_3_8_61_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-02001-1"},{"key":"e_1_3_8_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-021-03094-w"},{"key":"e_1_3_8_63_2","first-page":"521","article-title":"Long-term storage stability of an Excipient Enhanced Growth (EEG) pulmonary surfactant powder formulation","volume":"3","author":"Momin MAM","year":"2022","unstructured":"Momin MAM, , Farkas DR, , Longest W, et al. Long-term storage stability of an Excipient Enhanced Growth (EEG) pulmonary surfactant powder formulation. Respiratory Drug Delivery, 2022; 3:521\u2013526.","journal-title":"Respiratory Drug Delivery"},{"key":"e_1_3_8_64_2","first-page":"499","article-title":"In vitro evaluation of dry powder aerosol delivery efficiency to the lungs of preterm infants using two administration approaches","volume":"1","author":"Farkas DR","year":"2022","unstructured":"Farkas DR, , Hindle M, , Longest PW. In vitro evaluation of dry powder aerosol delivery efficiency to the lungs of preterm infants using two administration approaches. Respiratory Drug Delivery, 2022; 1:499\u2013504.","journal-title":"Respiratory Drug Delivery"},{"key":"e_1_3_8_65_2","first-page":"536","article-title":"Comparison of in vitro aerosol performance and powder characterization of a Synthetic Lung Surfactant (SLS) powder aerosol formulation produced using two spray drying methods","volume":"1","author":"Hall FG","year":"2024","unstructured":"Hall FG, , Momin MAM, , Farkas DR, et al. Comparison of in vitro aerosol performance and powder characterization of a Synthetic Lung Surfactant (SLS) powder aerosol formulation produced using two spray drying methods. Respiratory Drug Delivery, 2024; 1:536\u2013539.","journal-title":"Respiratory Drug Delivery"},{"key":"e_1_3_8_66_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1535-4"},{"key":"e_1_3_8_67_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0281-y"},{"key":"e_1_3_8_68_2","first-page":"540","article-title":"Efficient delivery of powder aerosol to the lungs of small animals with a new air-jet dry powder insufflator","volume":"1","author":"Pangeni R","year":"2024","unstructured":"Pangeni R, , Hassan A, , Farkas D, et al. Efficient delivery of powder aerosol to the lungs of small animals with a new air-jet dry powder insufflator. Respiratory Drug Deliv, 2024; 1:540\u2013543.","journal-title":"Respiratory Drug Deliv"},{"key":"e_1_3_8_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03409-5"},{"key":"e_1_3_8_70_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.06271"},{"key":"e_1_3_8_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1950050104"},{"key":"e_1_3_8_72_2","doi-asserted-by":"publisher","DOI":"10.1136\/fn.78.1.F3"},{"key":"e_1_3_8_73_2","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.933678"},{"key":"e_1_3_8_74_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198506000-00014"},{"issue":"2","key":"e_1_3_8_75_2","first-page":"173","article-title":"A novel swine model of ricin-induced acute respiratory distress syndrome","volume":"10","author":"Katalan S","year":"2017","unstructured":"Katalan S, , Falach R, , Rosner A, et al. A novel swine model of ricin-induced acute respiratory distress syndrome. Dis Model Mech, 2017; 10(2):173\u2013183; doi: 10.1242\/dmm.027847","journal-title":"Dis Model Mech"},{"issue":"1","key":"e_1_3_8_76_2","first-page":"251","article-title":"Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: Summary of clinical trials","volume":"5","author":"Logan JW","year":"2009","unstructured":"Logan JW, , Moya FR. Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: Summary of clinical trials. Ther Clin Risk Manag, 2009; 5(1):251\u2013260; doi: 10.2147\/tcrm.s4029","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_3_8_77_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1504025112"},{"key":"e_1_3_8_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2022.02.054"},{"key":"e_1_3_8_79_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2021-321645"},{"key":"e_1_3_8_80_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-3442"},{"key":"e_1_3_8_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/pxaa116"},{"key":"e_1_3_8_82_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072788"},{"key":"e_1_3_8_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911783"},{"key":"e_1_3_8_84_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2021.0057"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jamp.2025.0001","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2025.0001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2025.0001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:11:55Z","timestamp":1777644715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jamp.2025.0001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8,1]]}},"alternative-id":["10.1089\/jamp.2025.0001"],"URL":"https:\/\/doi.org\/10.1089\/jamp.2025.0001","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}